Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors

Journal of Infectious Diseases

Volumn 205, Issue 6, 2012, Pages 875-885

  Delwart, Eric ^a,b   Slikas, Elizabeth ^a   Stramer, Susan L ^c   Kamel, Hany ^d   Kessler, Debra ^e   Krysztof, David ^c   Tobler, Leslie H ^a   Carrick, Danielle M ^f   Steele, Whitney ^f   Todd, Deborah ^f   Wright, David J ^f   Kleinman, Steven H ^f,g   Busch, Michael P ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMERICAN RED CROSS   (United States)

^d Blood Systems Incorporated   (United States)

^e NEW YORK BLOOD CENTER   (United States)

^f WESTAT   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ANTIBODY TITER; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; VIRAL GENETICS; VIRUS GENOME; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADULT; AGED; BLOOD DONORS; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SEQUENCE ANALYSIS, DNA; SPECIMEN HANDLING; YOUNG ADULT;

EID: 84857574097     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir862     Document Type: Article

References (50)

1. Zou S, Stramer SL, Notari EP, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009;49:1609-20.
2. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495-504.
3. Brennan CA, Stramer SL, Holzmayer V, et al. Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion 2009;49:125-33.
4. Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011;364:236-47.
5. Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 2010;24:2763-71.
6. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998;280:42-8.
7. Machado DM, Delwart EL, Diaz RS, et al. Use of the sensitive/ lesssensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors. AIDS 2002;16:113-19.
8. Rawal BD, Degula A, Lebedeva L, et al. Development of a new lesssensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr 2003;33:349-55.
9. Shafer RW, Hertogs K, Zolopa AR, et al. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol 2001;39:1522-9.
10. Bernardin F, Tobler L, Walsh I, Williams JD, Busch M, Delwart E. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008;47:1446-52.
11. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-23.
12. Gifford RJ, Liu TF, Rhee SY, et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009;25:1197-8.
13. Shafer RW, Jung DR, Betts BJ. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med 2000;6:1290-2.
14. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31:298-303.
15. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-800.
16. Alcantara LC, Cassol S, Libin P, et al. A standardized framework for accurate, high-throughput genotyping of recombinant and nonrecombinant viral sequences. Nucleic Acids Res 2009;37:W634-42.
17. Myers R, Clark C, Khan A, Kellam P, Tedder R. Genotyping hepatitis B virus from whole-and sub-genomic fragments using position-specific scoring matrices in HBV STAR. J Gen Virol 2006;87:1459-64.
18. Gauthier M, Bonnaud B, Arsac M, et al. Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome. J Clin Microbiol 2010;48:4207-15.
19. Tran N, Berne R, Chann R, et al. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol 2006;44:2792-800.
20. Brennan CA, Yamaguchi J, Devare SG, Foster GA, Stramer SL. Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007. Transfusion 2010;50:2707-12.
21. Delwart E, Kuhns MC, Busch MP. Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: implications for blood safety, diagnostics, treatment, and molecular epidemiology. J Med Virol 2006;78(Suppl 1): S30-5.
22. Delwart EL, Orton S, Parekh B, Dobbs T, Clark K, Busch MP. Two percent of HIV-positive U. S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retroviruses 2003;19:1065-70.
23. de Oliveira CF, Diaz RS, Machado DM, et al. Surveillance of HIV-1 genetic subtypes and diversity in the US blood supply. Transfusion 2000;40:1399-406.
24. Thomson MM, Najera R. Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into Western countries. Clin Infect Dis 2001;32:1732-7.
25. Achkar JM, Burda ST, Konings FA, et al. Infection with HIV type 1 group M non-B subtypes in individuals living in New York City. J Acquir Immune Defic Syndr 2004;36:835-44.
26. Lin HH, Gaschen BK, Collie M, et al. Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquir Immune Defic Syndr 2006;41:399-404.
27. Singer DE, Bautista CT, O'Connell RJ, et al. HIV infection among U. S. Army and Air Force military personnel: sociodemographic and genotyping analysis. AIDS Res Hum Retroviruses 2010;26:889-94.
28. Brodine SK, Starkey MJ, Shaffer RA, et al. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 2003;17:2521-7.
29. Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev 2006;8:17-23.
30. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 2004;9:695-702.
31. Girardi E. Epidemiological aspects of transmitted HIV drug resistance. Scand J Infect Dis Suppl 2003;106:17-20.
32. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003;5:140-55.
33. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73.
34. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002;186:1558-64.
35. Herring BL, Page-Shafer K, Tobler LH, Delwart EL. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 2004;190:1396-403.
36. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009;200:1216-26.
37. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
38. Telles Dias P, Hahn JA, Delwart E, et al. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis 2011;11:208.
39. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267-80.
40. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-63.
41. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine-and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001;8:237-47.
42. Song BC, Kim SH, Kim H, et al. Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. J Med Virol 2005;76:194-202.
43. Echevarria JM, Avellon A. Hepatitis B virus genetic diversity. J Med Virol 2006;78(Suppl 1): S36-42.
44. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-8.
45. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004;189:2174-80.
46. Brennan CA, Bodelle P, Coffey R, et al. HIV global surveillance: foundation for retroviral discovery and assay development. J Med Virol 2006;78(Suppl 1): S24-9.
47. Peeters M, Aghokeng AF, Delaporte E. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin Microbiol Infect 2010;16:1525-31.
48. Jongerius JM, Wester M, Cuypers HT, et al. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998;38:56-9.
49. Avellon A, Echevarria JM, Weber B, et al. European collaborative evaluation of the Enzygnost HBsAg 6.0 assay: performance on hepatitis B virus surface antigen variants. J Med Virol 2011;83:95-100.
50. Scheiblauer H, El-Nageh M, Diaz S, et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang 2010;98:403-14.